Ranolazine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Ranolazine" in English language version.

refsWebsite

Global rank English rank

12nih.gov

4^th place

9doi.org

2^nd place

4web.archive.org

1^st place

2tga.gov.au

3,984^th place

2,622^nd place

2clincalc.com

3,912^th place

2,496^th place

2gilead.com

low place

2semanticscholar.org

11^th place

8^th place

2fda.gov

447^th place

338^th place

1hres.ca

low place

1drugs.com

399^th place

333^rd place

1thefreelibrary.com

518^th place

331^st place

1prnewswire.com

406^th place

258^th place

1thepharmaletter.com

low place

1nytimes.com

7^th place

1menariniapac.com

low place

1europa.eu

68^th place

117^th place

1eurekalert.org

3,538^th place

3,083^rd place

clincalc.com

"The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
"Atomoxetine - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.

doi.org

Banon D, Filion KB, Budlovsky T, Franck C, Eisenberg MJ (March 2014). "The usefulness of ranolazine for the treatment of refractory chronic stable angina pectoris as determined from a systematic review of randomized controlled trials". The American Journal of Cardiology. 113 (6): 1075–1082. doi:10.1016/j.amjcard.2013.11.070. PMID 24462341.
Rosa GM, Dorighi U, Ferrero S, Brunacci M, Bertero G, Brunelli C (June 2015). "Ranolazine for the treatment of atrial fibrillation". Expert Opinion on Investigational Drugs. 24 (6): 825–836. doi:10.1517/13543784.2015.1036984. PMID 25872749. S2CID 31659714.
De Vecchis R, Ariano C, Giasi A, Cioppa C (June 2018). "Antiarrhythmic effects of ranolazine used both alone for prevention of atrial fibrillation and as an add-on to intravenous amiodarone for its pharmacological cardioversion: a meta-analysis". Minerva Cardioangiologica. 66 (3): 349–359. doi:10.23736/S0026-4725.17.04349-3. PMID 28497941.
Kloner RA, Hines ME, Geunes-Boyer S (November 2013). "Efficacy and safety of ranolazine in patients with chronic stable angina". Postgraduate Medicine. 125 (6): 43–52. doi:10.3810/pgm.2013.11.2711. PMID 24200760. S2CID 2084618.
Noble D, Noble PJ (July 2006). "Late sodium current in the pathophysiology of cardiovascular disease: consequences of sodium-calcium overload". Heart. 92 (Suppl 4): iv1–iv5. doi:10.1136/hrt.2005.078782. PMC 1861316. PMID 16775091.
Sokolov S, Peters CH, Rajamani S, Ruben PC (2013). "Proton-dependent inhibition of the cardiac sodium channel Nav1.5 by ranolazine". Frontiers in Pharmacology. 4: 78. doi:10.3389/fphar.2013.00078. PMC 3689222. PMID 23801963.
Thomsen MB, Matz J, Volders PG, Vos MA (October 2006). "Assessing the proarrhythmic potential of drugs: current status of models and surrogate parameters of torsades de pointes arrhythmias". Pharmacology & Therapeutics. 112 (1): 150–70. doi:10.1016/j.pharmthera.2005.04.009. PMID 16714061.
Banerjee K, Ghosh RK, Kamatam S, Banerjee A, Gupta A (January 2017). "Role of Ranolazine in cardiovascular disease and diabetes: Exploring beyond angina". International Journal of Cardiology. 227: 556–564. doi:10.1016/j.ijcard.2016.10.102. PMID 27838121.
Redondo-Muñoz M, Rodriguez-Baena FJ, Aldaz P, Caballé-Mestres A, Moncho-Amor V, Otaegi-Ugartemendia M, et al. (September 2023). "Metabolic rewiring induced by ranolazine improves melanoma responses to targeted therapy and immunotherapy". Nature Metabolism. 5 (9): 1544–1562. doi:10.1038/s42255-023-00861-4. PMC 10513932. PMID 37563469.

drugs.com

"Ranolazine Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 22 March 2019.

eurekalert.org

Eureka Alert: Electrical signals between skin cells may influence melanoma initiation

europa.eu

ema.europa.eu

EMEA Ranolazine page at the EMEA Archived 5 October 2016 at the Wayback Machine

fda.gov

"FDA Approves New Treatment for Chest Pain". FDA News. 31 January 2006. Retrieved 2 March 2011.
"Cardiovascular and Renal Drugs Advisory Committee Briefing Document" (PDF). Food and Drug Administration.

gilead.com

"Ranexa (ranolazine) Extended-Release Tablets, for Oral Use. Full Prescribing Information". Gilead Sciences, Inc. Foster City, CA 94404. Retrieved 8 September 2016.
"Gilead Sciences Announces Fourth Quarter and Full Year 2016 Financial Results". Gilead.

hres.ca

hpr-rps.hres.ca

"Summary Basis of Decision (SBD) for Corzyna". Health Canada. 23 October 2014. Retrieved 29 May 2022.

menariniapac.com

Menarini press release. 18 June 2013 Memarii Group announces agreement with Gilead Sciences to commercialize Ranexa® (ranolazine) in 50 new countries Archived 7 November 2017 at the Wayback Machine

nih.gov

pubmed.ncbi.nlm.nih.gov

Banon D, Filion KB, Budlovsky T, Franck C, Eisenberg MJ (March 2014). "The usefulness of ranolazine for the treatment of refractory chronic stable angina pectoris as determined from a systematic review of randomized controlled trials". The American Journal of Cardiology. 113 (6): 1075–1082. doi:10.1016/j.amjcard.2013.11.070. PMID 24462341.
Rosa GM, Dorighi U, Ferrero S, Brunacci M, Bertero G, Brunelli C (June 2015). "Ranolazine for the treatment of atrial fibrillation". Expert Opinion on Investigational Drugs. 24 (6): 825–836. doi:10.1517/13543784.2015.1036984. PMID 25872749. S2CID 31659714.
De Vecchis R, Ariano C, Giasi A, Cioppa C (June 2018). "Antiarrhythmic effects of ranolazine used both alone for prevention of atrial fibrillation and as an add-on to intravenous amiodarone for its pharmacological cardioversion: a meta-analysis". Minerva Cardioangiologica. 66 (3): 349–359. doi:10.23736/S0026-4725.17.04349-3. PMID 28497941.
Kloner RA, Hines ME, Geunes-Boyer S (November 2013). "Efficacy and safety of ranolazine in patients with chronic stable angina". Postgraduate Medicine. 125 (6): 43–52. doi:10.3810/pgm.2013.11.2711. PMID 24200760. S2CID 2084618.
Noble D, Noble PJ (July 2006). "Late sodium current in the pathophysiology of cardiovascular disease: consequences of sodium-calcium overload". Heart. 92 (Suppl 4): iv1–iv5. doi:10.1136/hrt.2005.078782. PMC 1861316. PMID 16775091.
Sokolov S, Peters CH, Rajamani S, Ruben PC (2013). "Proton-dependent inhibition of the cardiac sodium channel Nav1.5 by ranolazine". Frontiers in Pharmacology. 4: 78. doi:10.3389/fphar.2013.00078. PMC 3689222. PMID 23801963.
Thomsen MB, Matz J, Volders PG, Vos MA (October 2006). "Assessing the proarrhythmic potential of drugs: current status of models and surrogate parameters of torsades de pointes arrhythmias". Pharmacology & Therapeutics. 112 (1): 150–70. doi:10.1016/j.pharmthera.2005.04.009. PMID 16714061.
Banerjee K, Ghosh RK, Kamatam S, Banerjee A, Gupta A (January 2017). "Role of Ranolazine in cardiovascular disease and diabetes: Exploring beyond angina". International Journal of Cardiology. 227: 556–564. doi:10.1016/j.ijcard.2016.10.102. PMID 27838121.
Redondo-Muñoz M, Rodriguez-Baena FJ, Aldaz P, Caballé-Mestres A, Moncho-Amor V, Otaegi-Ugartemendia M, et al. (September 2023). "Metabolic rewiring induced by ranolazine improves melanoma responses to targeted therapy and immunotherapy". Nature Metabolism. 5 (9): 1544–1562. doi:10.1038/s42255-023-00861-4. PMC 10513932. PMID 37563469.

ncbi.nlm.nih.gov

Noble D, Noble PJ (July 2006). "Late sodium current in the pathophysiology of cardiovascular disease: consequences of sodium-calcium overload". Heart. 92 (Suppl 4): iv1–iv5. doi:10.1136/hrt.2005.078782. PMC 1861316. PMID 16775091.
Sokolov S, Peters CH, Rajamani S, Ruben PC (2013). "Proton-dependent inhibition of the cardiac sodium channel Nav1.5 by ranolazine". Frontiers in Pharmacology. 4: 78. doi:10.3389/fphar.2013.00078. PMC 3689222. PMID 23801963.
Redondo-Muñoz M, Rodriguez-Baena FJ, Aldaz P, Caballé-Mestres A, Moncho-Amor V, Otaegi-Ugartemendia M, et al. (September 2023). "Metabolic rewiring induced by ranolazine improves melanoma responses to targeted therapy and immunotherapy". Nature Metabolism. 5 (9): 1544–1562. doi:10.1038/s42255-023-00861-4. PMC 10513932. PMID 37563469.

nytimes.com

Reuters, via the New York Times. 12 March 2009. Gilead, a White Knight, to Buy CV Therapeutics

prnewswire.com

CV Therapeutics, 22 June 2006 CV Therapeutics Acquires Rights to Ranolazine in Asia

semanticscholar.org

api.semanticscholar.org

Rosa GM, Dorighi U, Ferrero S, Brunacci M, Bertero G, Brunelli C (June 2015). "Ranolazine for the treatment of atrial fibrillation". Expert Opinion on Investigational Drugs. 24 (6): 825–836. doi:10.1517/13543784.2015.1036984. PMID 25872749. S2CID 31659714.
Kloner RA, Hines ME, Geunes-Boyer S (November 2013). "Efficacy and safety of ranolazine in patients with chronic stable angina". Postgraduate Medicine. 125 (6): 43–52. doi:10.3810/pgm.2013.11.2711. PMID 24200760. S2CID 2084618.

tga.gov.au

"Prescription medicines: registration of new chemical entities in Australia, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 9 April 2023.
"Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 31 March 2024.

thefreelibrary.com

CV Therapeutics press release. 1 April 1996 CV Therapeutics Licenses Late-Stage Anti-Anginal Drug from Syntex (U.S.A.), an Affiliate of Roche Holding Ltd. Archived 7 November 2017 at the Wayback Machine

thepharmaletter.com

Thepharmaletter.com 22 September 2008 Italy's Menarini to pay up to $385 million for rights to CV Thera's Ranexa

web.archive.org

"The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
CV Therapeutics press release. 1 April 1996 CV Therapeutics Licenses Late-Stage Anti-Anginal Drug from Syntex (U.S.A.), an Affiliate of Roche Holding Ltd. Archived 7 November 2017 at the Wayback Machine
Menarini press release. 18 June 2013 Memarii Group announces agreement with Gilead Sciences to commercialize Ranexa® (ranolazine) in 50 new countries Archived 7 November 2017 at the Wayback Machine
EMEA Ranolazine page at the EMEA Archived 5 October 2016 at the Wayback Machine